Corerx Pharma India Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 170.39%
- Profit Growth 438.53%
- Ebitda 307.24%
- Net Worth 501.14%
- Total Assets 70.12%
About Corerx Pharma India
Corerx Pharma India Private Limited (CPIPL) is a Private Limited Foreign Company Incorporated In India incorporated in India on 13 May 2021 (Three years and eight months 18 days old ). Its registered office is in Bangalore, Karnataka, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jayesh Patel and Aniket Manathkar serve as directors at the Company.
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24304KA2021FTC147384
- Company No.
147384
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
13 May 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Corerx Pharma India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayesh Patel  | Director | 13-May-2021 | Current |
| Aniket Manathkar | Director | 13-May-2021 | Current |
Financial Performance of Corerx Pharma India.
Corerx Pharma India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 170.39% increase. The company also saw a substantial improvement in profitability, with a 438.53% increase in profit. The company's net worth Soared by an impressive increase of 501.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Corerx Pharma India?
In 2023, Corerx Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jwi Ventures LlpJayesh Patel is a mutual person
- Gbas Technologies Private Limited
Jayesh Patel is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Corerx Pharma India?
Unlock and access historical data on people associated with Corerx Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Corerx Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Corerx Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.